Entheon Biomedical Corp. provided an update on its upcoming human trial, EBRX-101 and on nonclinical DMT initiatives. The Company announced that GMP DMT drug product has shipped from Ofichem Laboratorium to CHDR's partner pharmacy. Formulation and stability testing of the DMT drug product by CHDR's partner pharmacy has commenced in accordance with the projected start date of EBRX-101, a study that will evaluate the pharmacodynamics, pharmacokinetics and safety of a target controlled intravenous infusion of N, N-dimethyltryptamine ("DMT") in a population of healthy smokers. With the understanding that DMT possesses a favourable safety and toxicology profile based on historical preclinical and clinical research, Entheon has embarked on several pre-clinical studies to further characterize the drug in support of Entheon's specific clinical pathway and to satisfy anticipated requirements for a future meeting with the FDA. In connection with its nonclinical program, Entheon announced that in vitro HERG and genotox assays have been completed, and in vivo toxicity assays have commenced with final reports for both studies expected in the fourth quarter of 2021.